Innovaderm has received clearance from Health Canada to initiate a Phase I clinical trial to investigate the topical application of its lead photodynamic therapy compound ACP-SL017 as a treatment for acne.

This study will be conducted in addition to a Phase I clinical trial of ACP-SL017 for photodynamic therapy of actinic keratosis, taking place at the University of Alberta. The acne trial is designed to evaluate the histological localization of ACP-SL017 after topical application to patients that have acne.